Bee, snake, and scorpion venom have cancer-fighting properties
the ONA take:
Finding reported at the 248th National Meeting of the American Chemical Society (ACS) suggest that bee, snake, or scorpion venom may be able to be used to fight cancer.
According to lead investigator Dipanjan Pan, Ph.D., the venom toxins within nanometer-sized particles were able to treat breast cancer and melanoma cells in vitro by remaining hidden from the immune system, thereby sparing normal cells and only killing cancer cells. This method eliminates adverse effects that venom toxins would typically cause.
Venom from these animals contains biological molecules that can attach to cancer cell membranes which would stop the growth and spread cancer. Because simply injecting venom into a patient would cause serious adverse effects like clotting, heart muscle or nerve cell damange, or bleeding under the skin, the anti-tumor substances within the venom had to be identified. One of those substances, melittin was chemically synthesized and inserted into nanoparticles.
The nanoparticles keep the toxin from seeping into the bloodstream and causing adverse effects. Pan says that the nanoparticles then go to the tumor where they attach to cancer stem cells, thereby blocking proliferation.
Future studies will evaluate this new method in rats and pigs, but Pan and his team hope they will eventually study the approach in patients in the next 3 to 5 years.
Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs.
The report was part of the 248th National Meeting of the American Chemical Society (ACS), the world's largest scientific society.
The meeting, attended by thousands of scientists, features nearly 12,000 reports on new advances in science and other topics. It is being held here through Thursday.
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Clinical Trials May Benefit Oncology Patients
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|